Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business

Executive Summary

Johnson & Johnson’s pharma business appears to be weathering headwinds that are hobbling its consumer and medical device sales. Pharma accounted for 36% of JNJ’s 2010 sales of $61.6 billion.

You may also be interested in...



Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?

J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.

Merck And J&J Settle Remicade Dispute By Redrawing The Map

Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs

Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain

Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel